PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding postmenopausal osteoporosis • Epidemiology and demography • Risk factors • Symptoms • Diagnosis • Treatment PART 06: Key buying criteria PART 07: Pipeline scenario • TBRIA • Romosozumab (AMG785) • Odanacatib (MK-0822) • Abaloparatide SC/Abaloparatide transdermal patch • PHN-031 (PH3) • NB S101 • Teriparatide ZP Patch (ZP-PTH) • Blosozumab (LY2541546) PART 08: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by therapeutic class • Antiresorptive medications • Anabolic medications PART 10: Market segmentation by line of therapy PART 11: Geographical segmentation • Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020 • Postmenopausal osteoporosis drugs market in Americas • Postmenopausal osteoporosis drugs market in EMEA • Postmenopausal osteoporosis drugs market in APAC PART 12: Market drivers • Increase in older population • Growing prevalence of postmenopausal osteoporosis • Expected launch of promising pipeline molecules • High unmet medical needs PART 13: Impact of drivers PART 14: Market challenges • Multiple patent expiries • Low diagnosis rate • Nonadherence to treatment regimen • Drug reimbursement issues PART 15: Impact of drivers and challenges PART 16: Market trends • Awareness programs and initiatives • Emergence of novel agents • Emergence of combination therapies PART 17: Vendor landscape • Competitive scenario • Market analysis 2015 • Eli Lilly • Amgen • Merck • Novartis • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Prevalence of osteoporosis based on gender 2015 Exhibit 03: Interpretation of BMD results Exhibit 04: Timeline for development of osteoporosis drugs Exhibit 05: Key buying criteria for postmenopausal osteoporosis drugs Exhibit 06: Pipeline portfolio: Postmenopausal osteoporosis Exhibit 07: Global postmenopausal osteoporosis drugs market 2015-2020 ($ billions) Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class Exhibit 10: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class on basis of revenue 2015 Exhibit 11: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy Exhibit 12: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy on basis of revenue 2015 Exhibit 13: Segmentation of global postmenopausal osteoporosis drugs market based on geography 2015 Exhibit 14: Global postmenopausal osteoporosis drugs market by geography 2015-2020 ($ billions) Exhibit 15: Global postmenopausal osteoporosis drugs market by geography 2015-2020 Exhibit 16: Postmenopausal osteoporosis drugs market in Americas 2015-2020 ($ billions) Exhibit 17: Postmenopausal osteoporosis drugs market in EMEA 2015-2020 ($ billions) Exhibit 18: Postmenopausal osteoporosis drugs market in APAC 2015-2020 ($ billions) Exhibit 19: Global postmenopausal osteoporosis drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 20: Percentage share of women in age group of 60 years and older 2015 Exhibit 21: Percentage share of women in age group of 80 years and above 2015 Exhibit 22: Impact of drivers Exhibit 23: Impact of drivers and challenges Exhibit 24: Revenue from sales of major drugs in global postmenopausal osteoporosis drugs market 2013-2015 ($ millions) Exhibit 25: Eli Lilly: YoY revenue and growth rate of FORTEO 2015 ($ billions) Exhibit 26: Eli Lilly: Geographical segmentation of FORTEO 2015 Exhibit 27: Eli Lilly: YoY revenue and growth rate of Evista 2015 ($ millions) Exhibit 28: Eli Lilly: Geographical segmentation of Evista 2015 Exhibit 29: Eli Lilly: Key takeaways Exhibit 30: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ millions) Exhibit 31: Amgen: Geographical segmentation of Prolia 2015 Exhibit 32: Amgen: Key takeaways Exhibit 33: Merck: YoY revenue and growth rate of Fosamax 2013-2015 ($ millions) Exhibit 34: Merck: Key takeaways Exhibit 35: Novartis: Key takeaways

Eli Lilly, Amgen, Merck, Novartis, Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group, Upsher-Smith Laboratories, Watson Pharmaceuticals, Zosano Pharma.